RAC1 and colonic neoplasm: GYS32661 is currently developed as an anticancer agent, essentially positioned to treat breast and colon cancers [125], but this potent Rac1 inhibitor could be envisioned for the treatment of other malignancies associated with an overactivation of Rac1, such as bladder cancers.